Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
11/2003
11/13/2003WO2003093297A2 Protein kinase modulators and methods of use
11/13/2003WO2003093270A1 5-ethyl-imidazo (5,1-f) (1,2,4,) triazin-4 (3h) -ones as phosphodiesterase inhibitors
11/13/2003WO2003093268A1 7-aminoimidazotriazones
11/13/2003WO2003093266A1 Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
11/13/2003WO2003093254A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003WO2003093248A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
11/13/2003WO2003093245A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
11/13/2003WO2003093238A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
11/13/2003WO2003093237A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
11/13/2003WO2003093236A1 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
11/13/2003WO2003093235A1 Carboxylic acid amides
11/13/2003WO2003093234A1 Melanocortin receptor ligands
11/13/2003WO2003093231A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092706A1 Re-epithelializing pharmaceutical compositions comprising xanthan gum
11/13/2003WO2003092703A1 Methods and compositions for inhibition or irritation by disaccharide and metal ions
11/13/2003WO2003092699A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003WO2003092697A1 Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
11/13/2003WO2003092693A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
11/13/2003WO2003092690A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003WO2003092689A1 The treatment of pain with ifendropil
11/13/2003WO2003092686A1 Inhibitors of histone deacetylase
11/13/2003WO2003092681A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases
11/13/2003WO2003092667A1 Composition for treating cancer containing n,n-dimethylphytosphingosine
11/13/2003WO2003092660A1 Monocompartment osmotic controlled drug delivery system
11/13/2003WO2003092647A2 Transport system in biological systems
11/13/2003WO2003092629A2 Methods of simultaneously treating mucositis and fungal infection
11/13/2003WO2003092613A2 Catechin multimers as therapeutic drug delivery agents
11/13/2003WO2003092608A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003WO2003092605A2 Protease inhibitors
11/13/2003WO2003092602A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003WO2003092599A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003WO2003092595A2 Tyrosine kinase inhibitors
11/13/2003WO2003092586A2 Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
11/13/2003WO2003092580A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003WO2003076417A3 Oxo-azabicyclic compounds
11/13/2003WO2003072090A3 Use of tyrosine kinase inhibitors for treating cns disorders
11/13/2003WO2003066621A8 Piperidine derivatives and their use as antagonists of tachykinins
11/13/2003WO2003064447A3 Immune-modulating peptide
11/13/2003WO2003061365A3 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
11/13/2003WO2003053331A3 Protease inhibitors
11/13/2003WO2003033653A3 Affinity enhancement agents
11/13/2003WO2003031459A3 Modulation of the expression of genes dependent on stat-1
11/13/2003WO2003031407A3 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
11/13/2003WO2003030944A3 Inhibition of stat-1
11/13/2003WO2003029221A8 Tetrahydroisochinolines, their production and the use thereof as analgesics
11/13/2003WO2003029200A3 Compounds useful as reversible inhibitors of cysteine proteases
11/13/2003WO2003027316A3 Methods of using 33751, a human potassium channel family member
11/13/2003WO2003022360A3 Thermotherapy via targeted delivery of nanoscale magnetic particles
11/13/2003WO2003018134A3 Bioadhesive compositions and methods for enhanced mucosal drug absorption
11/13/2003WO2003017939A3 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
11/13/2003WO2003013432A3 Methods of use for novel sulfur containing organic nitrate compounds
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
11/13/2003WO2003010281A3 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
11/13/2003WO2003009778A3 Methods and devices for delivery of therapeutic capable agents with variable release profile
11/13/2003WO2002099115A3 Nucleic acid-associated proteins
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003WO2002088137A9 Pkb-3564 substance with neovascularization inhibitory activity
11/13/2003WO2002083622A3 Novel aminophenyl ketone derivatives
11/13/2003WO2002072031A3 Substituted tetracycline compounds as synergistic antifungal agents
11/13/2003WO2002066681A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
11/13/2003WO2002057231A8 Benz(g) indoles and their use as spla2 inhibitors
11/13/2003WO2002050030A8 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
11/13/2003WO2002050029A8 Tetracyclic derivatives as spla2 inhibitors
11/13/2003WO2002048715A3 Inflammatory markers for detection and prevention of diabetes mellitus
11/13/2003WO2002016327A8 Benzimidazoles and analogues and their use as neutrophil inhibitors
11/13/2003US20030213003 Preparing and recoverng genetically engineered fusion protein for treating diabetes
11/13/2003US20030212273 Pyrrolo [2,3-D] pyrimidine compounds
11/13/2003US20030212269 Kinase inhibitor; antitumor agents, psoriasis, skin disorders, antiarthritic agents
11/13/2003US20030212140 Analgesics; central nervous system disorders
11/13/2003US20030212138 Synergistic mixture; analgesics, antiinflammatory agents, cardiovascular disorders, anticancer agents
11/13/2003US20030212114 Stable emulsion compositions
11/13/2003US20030212097 Osteoporosis, antiarthrtic agents; antitumor agents
11/13/2003US20030212093 Imidazonaphthyridines
11/13/2003US20030212091 Aryl ether substituted imidazoquinolines
11/13/2003US20030212082 Controlling neovascularization; angiogenesis inhibitors; therapy for strokes, cardiovascular disorders; antitumor agents; antidiabetic agents; antiarthritic agents; psoriasis
11/13/2003US20030212073 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
11/13/2003US20030212068 Antiinflammatory agents; antiallergens; antiarthritic agents
11/13/2003US20030212067 Bone disorders; rheumatic diseases; wound healing agents
11/13/2003US20030212057 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
11/13/2003US20030212055 Cinnoline compounds
11/13/2003US20030212036 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory heptitis
11/13/2003US20030212020 Antisense modulation of macrophage migration inhibitory factor expression
11/13/2003US20030211986 Protein a compositions and methods of use
11/13/2003US20030211577 Novel G protein-coupled receptor, GAVE7
11/13/2003US20030211513 Intracellular signaling proteins
11/13/2003US20030211493 Comprises membrane protein for diagnosis, prevention and treatment of infections, cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory and metabolic disorders
11/13/2003US20030211165 Anticancer agents; mixture of hydrophilic, crosslinked polymer and drugs
11/13/2003US20030211163 Combination antiviral therapy
11/13/2003US20030211145 Antiinflammatory agents, analgesics, antiarthritic agents; liquid filled capsulaes
11/13/2003US20030211106 Binding tumor necrosis factor to antibody
11/13/2003US20030211103 Use of primate IFN-gamma binding molecules
11/13/2003US20030211040 Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
11/13/2003CA2749172A1 Re-epithelializing pharmaceutical compositions comprising xanthan gum
11/13/2003CA2703698A1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003CA2500134A1 Methods of simultaneously treating mucositis and fungal infection
11/13/2003CA2485115A1 The treatment of pain with ifenprodil
11/13/2003CA2485065A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003CA2484983A1 5-ethyl-imidazo (5,1-f) (1,2,4,) triazin-4 (3h) -ones as phosphodiesterase inhibitors
11/13/2003CA2484874A1 Monocompartment osmotic controlled drug delivery system
1 ... 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 ... 1272